Target intelligence / Profile preview

Complement C5a anaphylatoxin (C5a)

Target
C5a
Molecular classification
Complement component, Anaphylatoxin, Peptide
01

Overview

Complement C5a and related anaphylatoxins (C3a, C4a) are potent bioactive protein fragments generated during the activation of the complement cascade (StatPearls: NBK534869). C5a is the most biologically active member, functioning as a powerful chemoattractant that recruits and activates neutrophils, monocytes, and macrophages to sites of inflammation. It exerts its effects primarily through the high-affinity G protein-coupled receptor C5aR1 (CD88) and the non-canonical receptor C5aR2 (UniProt: P21730). Dysregulation of the C5a-C5aR1 axis is a key driver in the pathogenesis of various inflammatory and autoimmune conditions, including ANCA-associated vasculitis, hidradenitis suppurativa, and severe COVID-19. Therapeutic strategies targeting this pathway include monoclonal antibodies that bind and neutralize C5a directly, as well as small molecule antagonists that block the C5aR1 receptor (FDA: 214472). These interventions aim to mitigate tissue damage caused by excessive leukocyte infiltration while preserving the terminal complement pathway's ability to form the membrane attack complex.

Other names
C5aC3aC4aAnaphylatoxinsComplement component 5aComplement component 3aComplement component 4aC5a receptor ligand
02

Mechanism of action

Inhibition of the anaphylatoxin signaling pathway through direct neutralization of the C5a ligand or competitive antagonism of the C5a receptor 1 (C5aR1), thereby preventing neutrophil activation and chemotaxis.

03

Biological functions

Immune responseSignal transductionChemotaxisInflammationLeukocyte activation
04

Disease associations

InflammationAutoimmune diseaseInfectionCardiovascular diseaseRenal disease
05

Safety considerations

Increased risk of pyogenic infectionsRisk of Neisseria meningitidis infectionPotential for liver enzyme elevationsImmunosuppression
06

Interacting drugs

8 more in the full profile.

07

Biomarkers

Plasma C5a levelsC5aR1 expressionNeutrophil activation markersCD11b expression

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Complement C5a anaphylatoxin (C5a).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Complement C5a anaphylatoxin (C5a).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call